Purpose The development of blood biomarkers that reflect Alzheimer's disease (AD)
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …

Neurodegenerative diseases (ND) remains to be one of the biggest burdens on healthcare
systems and serves as a leading cause of disability and death. Alzheimer's disease (AD) is …

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …

The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-
associated tau protein characterizes 80% of all dementia disorders, the most common …

Alzheimer's disease (AD) is the most common cause of dementia, affecting the central
nervous system (CNS) through the accumulation of intraneuronal neurofibrillary tau tangles …

Salivary analysis is gaining increasing interest as a novel and promising field of research for
the diagnosis of neurodegenerative and demyelinating diseases related to aging. The …

Neurodegeneration is a highly complex process which is associated with a variety of
molecular mechanisms related to ageing. Among neurodegenerative disorders, Alzheimer's …

Background. The histopathological changes of Alzheimer's disease (AD) are detectable
decades prior to its clinical expression. However, there is a need for an early, inexpensive …

The search for accessible and cost-effective biomarkers to complement current
cerebrospinal fluid (CSF) and imaging biomarkers in the accurate detection of Alzheimer …

Cellular accumulation of aggregated forms of the protein tau is a defining feature of so-
called tauopathies such as Alzheimer's disease, progressive supranuclear palsy, and …